TY - JOUR T1 - Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.254482 SP - jnumed.120.254482 AU - Ryusuke Nakamoto AU - Lisa C. Zaba AU - Tie Liang AU - Sunil Arani Reddy AU - Guido Davidzon AU - Carina Mari Aparici AU - Judy Nguyen AU - Farshad Moradi AU - Andrei Iagaru AU - Benjamin Lewis Franc Y1 - 2021/02/01 UR - http://jnm.snmjournals.org/content/early/2021/02/05/jnumed.120.254482.abstract N2 - Purpose: To investigate the prognostic value of 18F-FDG PET/CT parameters in melanoma patients before beginning anti-PD-1 therapy. Methods: Imaging parameters including SUVmax, metabolic tumor volume (MTV), and bone marrow to liver SUVmean ratio (BLR) were measured from baseline PET/CT in 92 patients before the start of anti-PD-1 therapy. Association with survival and imaging parameters combined with clinical factors was evaluated. Clinical and laboratory data between high (&gt; median) and low (≤ median) BLR groups were compared. Results: Multivariate analyses demonstrated that BLR was an independent prognostic factor for PFS and OS (P = 0.017, P = 0.011, respectively). The high BLR group had higher levels of white blood cell count/neutrophil count and C-Reactive Protein than the low BLR group (P &lt; 0.05). Conclusion: Patients with high BLR were associated with poor PFS and OS, potentially explained by evidence of systemic inflammation known to be associated with immunosuppression. ER -